Richard B. Warren

1. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
   2022/09/09 by Eric L. Simpson, Joseph F. Merola, Jonathan I. Silverberg +13 · 27 citations
   Medicine · #Dermatology and Skin Diseases #Asthma and respiratory diseases #Allergic Rhinitis and Sensitization
2. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
   2022/11/29 by Georgios Kokolakis, Richard B Warren, Richard B. Warren +16 · 9 citations
   Immunology and Microbiology · Medicine · Biochemistry, Genetics and Molecular Biology · #Psoriasis: Treatment and Pathogenesis #Spondyloarthritis Studies and Treatments #Inflammatory Bowel Disease
3. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
   2023/01/01 by April W. Armstrong, Melinda Gooderham, Richard B. Warren +13 · 1 citation
4. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
   2020/03/03 by Zenas Z N Yiu, Z.Z.N. Yiu, K.J. Mason +12 · 25 citations
   Immunology and Microbiology · Medicine · #Psoriasis: Treatment and Pathogenesis #Spondyloarthritis Studies and Treatments #Dermatology and Skin Diseases